PEN — Penumbra, Inc.

Summary of Penumbra's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $354.7 million, up 17.8% year-over-year (16.9% on a constant currency basis).
• U.S. Revenue: $275 million, a 21.5% increase year-over-year.
• Gross Margin: 67.8%, improved by 130 basis points from the previous year.
• Operating Income: $48.8 million, representing 13.8% of revenue, compared to $40.3 million (13.4% of revenue) in Q3 2024.
• Adjusted EBITDA: $66.7 million, or 18.8% of total revenue, consistent with the previous year.
• Cash Position: $470.3 million in cash and marketable securities, with no debt.

2. Strategic Updates and Business Highlights

• Product Performance: Strong growth in the U.S. thrombectomy sales (up 18.5% to $192 million) and embolization/access revenue (up 29.2% to $83 million) driven by the Ruby XL product and a dedicated sales team.
• International Revenue: Increased by 6.6% year-over-year, with improvements in regions outside of China.
• Clinical Trials: Positive results from the STORM-PE trial, which is expected to catalyze the adoption of CAVT technology for treating pulmonary embolism (PE).
• New Product Launches: FDA clearance received for Lightning Bolt 16 and Lightning Flash 3.0, enhancing the CAVT product portfolio.
• Sales Team Expansion: Successful integration of a new dedicated embolization sales team, contributing to sequential growth.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised to $1.375 billion to $1.380 billion for the full year 2025, reflecting continued growth expectations.
• U.S. Thrombectomy Growth: Reiterated guidance of 20% to 21% year-over-year growth for 2025.
• Long-term Goals: Aiming for gross margins over 70% by the end of 2026, with operating margin expansion expected to outpace gross margin growth.

4. Bad News, Challenges, or Points of Concern

• International Headwinds: Continued challenges in the Chinese market, although easing, are still impacting overall international growth.
• Stroke Market Decline: A slight decline in the U.S. stroke market was noted, which could affect future growth in that segment.
• Regulatory Risks: Ongoing FDA review process for the Thunderbolt product, with potential delays and uncertainties regarding additional testing or data requirements.
• Operating Expenses: Increased SG&A expenses (up 25% year-over-year) due to the expansion of the sales team, which may pressure margins in the short term.

5. Notable Q&A Insights

• Thunderbolt Product Launch: Management expressed optimism about the FDA approval process but emphasized the thoroughness required for new product approvals.
• STORM-PE Impact: Positive feedback from the medical community regarding STORM-PE results, with expectations for increased adoption of CAVT technology.
• Market Dynamics: Management acknowledged the cyclical nature of the stroke market and indicated that new technologies could catalyze future growth.
• Embolization and Access Growth: The dedicated sales team is expected to sustain growth in the embolization segment, with ongoing physician interest in new products contributing to market expansion.

This summary encapsulates the key elements from Penumbra's Q3 2025 earnings call, highlighting financial performance, strategic initiatives, and outlook while addressing potential challenges and insights from the Q&A session.